• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

大剂量甲氨蝶呤联合亚叶酸钙和长春新碱治疗恶性间皮瘤。

High-dose methotrexate with citrovorum factor and vincristine in the treatment of malignant mesothelioma.

作者信息

Dimitrov N V, Egner J, Balcueva E, Suhrland L G

出版信息

Cancer. 1982 Oct 1;50(7):1245-7. doi: 10.1002/1097-0142(19821001)50:7<1245::aid-cncr2820500704>3.0.co;2-h.

DOI:10.1002/1097-0142(19821001)50:7<1245::aid-cncr2820500704>3.0.co;2-h
PMID:6980698
Abstract

The incidence of malignant mesothelioma has increased greatly in the last 40 years. Current and recent past exposure to asbestos is expected to substantially increase this incidence. We report nine cases of malignant mesothelioma which temporarily responded to treatment with high-dose methotrexate-citrovorum rescue and vincristine. Further clinical trials of high-dose methotrexate with citrovorum rescue appear indicated in this disease.

摘要

在过去40年中,恶性间皮瘤的发病率大幅上升。目前及近期接触石棉预计会大幅增加这一发病率。我们报告了9例恶性间皮瘤病例,这些病例对大剂量甲氨蝶呤-亚叶酸解救疗法和长春新碱治疗有暂时反应。大剂量甲氨蝶呤联合亚叶酸解救疗法的进一步临床试验似乎适用于这种疾病。

相似文献

1
High-dose methotrexate with citrovorum factor and vincristine in the treatment of malignant mesothelioma.大剂量甲氨蝶呤联合亚叶酸钙和长春新碱治疗恶性间皮瘤。
Cancer. 1982 Oct 1;50(7):1245-7. doi: 10.1002/1097-0142(19821001)50:7<1245::aid-cncr2820500704>3.0.co;2-h.
2
High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study.高剂量甲氨蝶呤治疗胸膜恶性间皮瘤:一项II期研究
Br J Cancer. 1992 Jun;65(6):956-60. doi: 10.1038/bjc.1992.200.
3
[Treatment of diffuse malignant mesothelioma of the pleura].[胸膜弥漫性恶性间皮瘤的治疗]
Tidsskr Nor Laegeforen. 1988 Nov 30;108(33):3091-3.
4
Malignant mesotheliomas and chemotherapy.
J Surg Oncol. 1980;15(2):181-5. doi: 10.1002/jso.2930150209.
5
Chemotherapy of malignant diffuse mesothelioma.恶性弥漫性间皮瘤的化疗
Cancer. 1976 Mar;37(3):1265-74. doi: 10.1002/1097-0142(197603)37:3<1265::aid-cncr2820370306>3.0.co;2-q.
6
Chemotherapy for malignant mesothelioma; CAMEO.恶性间皮瘤的化疗;CAMEO。
Am J Clin Oncol. 1982 Aug;5(4):429-31. doi: 10.1097/00000421-198208000-00014.
7
A phase II study of vincristine in malignant mesothelioma--a negative report.
Cancer Chemother Pharmacol. 1989;24(2):133-4. doi: 10.1007/BF00263135.
8
[Malignant mesothelioma of the peritoneum. Case report].
Zentralbl Gynakol. 1983;105(9):598-601.
9
High dose methotrexate with citrovorum factor in adult resistant lymphoma.大剂量甲氨蝶呤联合亚叶酸钙治疗成人难治性淋巴瘤
Cancer. 1977 Dec;40(6):2823-8. doi: 10.1002/1097-0142(197712)40:6<2823::aid-cncr2820400612>3.0.co;2-2.
10
Continuous infusion vincristine and bleomycin with high dose methotrexate for resistant non-Hodgkin's lymphoma.持续输注长春新碱和博来霉素联合大剂量甲氨蝶呤治疗难治性非霍奇金淋巴瘤。
Cancer. 1982 Nov 1;50(9):1690-4. doi: 10.1002/1097-0142(19821101)50:9<1690::aid-cncr2820500906>3.0.co;2-z.

引用本文的文献

1
Chemotherapy for malignant pleural mesothelioma: past results and recent developments.恶性胸膜间皮瘤的化疗:既往结果与近期进展
Br J Cancer. 2003 Jan 27;88(2):167-74. doi: 10.1038/sj.bjc.6600673.
2
Current therapy for malignant mesothelioma.恶性间皮瘤的当前治疗方法。
Curr Oncol Rep. 2002 Jul;4(4):305-13. doi: 10.1007/s11912-002-0006-2.
3
High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma.大剂量甲氨蝶呤联合干扰素治疗恶性胸膜间皮瘤
Br J Cancer. 1999 Aug;80(11):1781-5. doi: 10.1038/sj.bjc.6690597.
4
Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients.胸膜恶性间皮瘤:52例接受治疗患者和64例未接受治疗患者的研究。
Thorax. 1984 Apr;39(4):255-9. doi: 10.1136/thx.39.4.255.
5
Chemotherapy in malignant mesothelioma: a review.恶性间皮瘤的化疗:综述
Cancer Chemother Pharmacol. 1991;28(5):319-30. doi: 10.1007/BF00685684.
6
High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study.高剂量甲氨蝶呤治疗胸膜恶性间皮瘤:一项II期研究
Br J Cancer. 1992 Jun;65(6):956-60. doi: 10.1038/bjc.1992.200.